Form 4: Artivion SVP Sells Over 26,000 Shares Under Pre-Arranged Trading Plan

Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., has sold a total of 26,132 shares of common stock on June 13, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Marshall S. Stanton, the Senior Vice President of Clinical & MD Affairs at Artivion, Inc. (AORT), reported the sale of 26,132 shares of the company's common stock.
• The transactions occurred on June 13, 2025, and were executed under a Rule 10b5-1 trading plan adopted by Mr. Stanton on March 14, 2025.
• The sales were conducted in four separate transactions at weighted average prices ranging from $28.4217 to $28.4666 per share.
• Specifically, 8,747 shares were sold at a weighted average price of $28.4615, 1,253 shares at $28.4666, 14,306 shares at $28.4217, and 1,826 shares at $28.4277.
• The shares sold originated from Performance Stock Units and the Employee Stock Purchase Plan.
• Following these transactions, Mr. Stanton beneficially owns 79,200 shares of Artivion, Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that these sales were conducted under a pre-arranged 10b5-1 plan significantly mitigates any negative implications, as it suggests the sales were for personal financial planning rather than based on new, adverse company information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which indicates the transactions were pre-scheduled and not based on new, non-public information, thereby reducing concerns about opportunistic insider selling.

Negatives

• The sale of a significant number of shares by a senior executive, even under a 10b5-1 plan, could be perceived negatively by some investors as it reduces the executive's direct equity stake in the company.

Future Outlook

N/A

Management Comments

• The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. Such filings are common across all publicly traded companies as executives manage their personal portfolios and compensation.

Stakeholder Impact

• Shareholders: The sale of shares by a senior executive could lead to minor concerns about management's confidence, though the 10b5-1 plan mitigates this. It also slightly increases the float of shares available in the market.

Key Dates

Keywords

Artivion, AORT, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, SEC Filing, Common Stock